Dual inhibition of CDK4/6 and XPO1 induced senescence with acquired vulnerability to CRBN-based PROTAC drugs.
We first treated senescent  liver cancer cells with vehicle or ARV-825 for 48 hours. Then, RNA sequencing was conducted to quantify the mRNA expression level of vehicle-treated or ARV-825-treated liver cancer cells. ARV-825-induced expression changes were obtained based on the resultant data. Overall design: Examination of the transcriptome changes of senescence liver cancer cells treated with ARV-825